No3(3) 2020
Back to the issue
|
DOI 10.37219/2528-8253-2020-3-04 |
Bakaev A.A., Kovtunenko O.V., Tymchuk S.M.
Analysis of remote results of treatment of patients with maxillary sinus
cancer |
Bakaev Anatoly A.
State Institution "Dnipropetrovsk Medical Academy of the Ministry of Health
of Ukraine"
Department of Otolaryngology, Graduate student
Municipal enterprise «Dnipropetrovsk Regional Clinical Hospital named after
I.I. Mechnikov» Dnipropetrovsk Regional Council
Department of Otorhinolaryngology No. 2 (oncological)
Otolaryngologist
Email: anatoliybakaev@gmail.com
Orchid ID: https://orcid.org/0000-0003-4192-7614
Kovtunenko Alexander V.
State Institution "Dnipropetrovsk Medical Academy of the Ministry of Health
of Ukraine"
Professor of the Department of Otolaryngology
Doctor of Medical Sciences
Email: lor@dsma.dp.ua
Orchid ID: https://orcid.org/0000-0002-0562-7684
Tymchuk Sergey N.
Municipal enterprise «Dnipropetrovsk Regional Clinical Hospital named after
I.I. Mechnikov» Dnipropetrovsk Regional Council
Head of the Department of Otorhinolaryngology No. 2 (oncological)
Doctor of Medical Sciences
Email: sergej_lor@ukr.net
Orchid ID: https://orcid.org/0000-0002-8706-2313 |
|
Abstract
Maxillary sinus cancer is one of the most complex malignancies to treat and
has an unfavorable prognosis for long-term outcomes.
The purpose of the study: based on the evaluation of long-term
treatment outcomes (mortality, survival) to analyze the effectiveness of
treatment of patients with maxillary sinus cancer and other factors which
influence the outcome, including the level of expression of molecular
markers.
Object and methods: Long-term results of surgical treatment of 103
patients with maxillary sinus cancer stage II-IV (T2-4N0-3M0)
were evaluated, which was performed in the ENT oncology department of І.І.
Mechnikov Dnipropetrovsk Regional Clinical Hospital over the period of
2011-2017. Remote follow-up of patients was conducted until 2019.
Results: The effectiveness of the treatment is confirmed by the
analysis of survival in the studied sample: annual survival of 87.36% (95%
CI 80.94-93.78); three-years’ survival – 42.75% (95% CI 33.2-52.3);
five-years’ survival – 19.76% (95% CI 12.07-27.45); median survival – 32.13
(95% CI 27.0-53.0) months.
Using a regression analysis of the proportional risks by Cox, it was proved
that patients with recurrences of thyroid cancer die from cancer 3.13 times
more often (p=0.009) than individuals in whom cancer was not accompanied by
recurrence, with increasing expression of the marker TIMP-1 per unit the
risk of adverse outcomes for patients is reduced by 2.56 times (p=0.034).
Conclusions: Evaluation of long-term treatment outcomes (mortality,
one-, three-, and five-years’ survival) of patients with maxillary sinus
cancer has proven the effectiveness of treatment and approaches to their
determination. |
|
Keywords
maxillary sinus cancer, molecular markers, mortality, survival. |
|
Reference
- Ansa B, Goodman M, Ward K, Kono SA, Owonikoko TK, Higgins K, et al.
Paranasal sinus squamous cell carcinoma incidence and survival based of
surveillance, epidemiology, and end results data, 1973 to 2009. Cancer.
2013;119(14):2602-10. doi: 10.1002/cncr.28108.
- Chen MM, Roman SA, Sosa JA, Judson BL. Predictors of Survival in
Sinonasal Adenocarcinoma. J NeurolSurg B Skull Base. 2015
Jun;76(3):208-13. doi: 10.1055/s-0034-1543995.
- Dubal PM, Bhojwani A, Patel TD, Zuckerman O, Baredes S, Liu JK, et
al. Squamous cell carcinoma of the maxillary sinus: A population-based
analysis. Laryngoscope. 2016 Feb;126(2):399-404. doi:
10.1002/lary.25601.
- Harvey RJ, Dalgorf DM. Chapter 10: Sinonasal malignancies. Am J
Rhinol Allergy. May-Jun 2013;27 Suppl 1:S35-8. doi:
10.2500/ajra.2013.27.3894.
- Jain S, Li Y, Kuan EC, Tajudeen BA, Batra PS. Prognostic Factors in
Paranasal Sinus Squamous Cell Carcinoma and Adenocarcinoma: A SEER
Database Analysis. J Neurol Surg B Skull Base. 2019 Jun;80(3):258-263.
doi: 10.1055/s-0038-1669420.
- Kovtunenko OV, Bakaiev АА, Shponka IS. Analysis of expression of p63
and caspase-3 and theirpredictivevalue in patients with squamous cell
carcinoma of maxillary sinus. Wiadomości Lekarskie. 2019; LXXII(12.I):
2305-14. doi: 10.36740/WLek201912108.
- Kreppel M, Danscheid S, Scheer M, Lьers JC, Eich HT, Zцller JE, etal.
Neoadjuvant chemoradiation in squamous cell carcinoma of the maxillary
sinus: a 26-year experience. Chemother Res Pract. 2012;2012:413589. doi:
10.1155/2012/413589.
- Lukach E, Serezhko Ju, Ternyc’ka Ju. [Tumors of the nose and
paranasal sinuses]. Rynologija. 2006;4:3-13. [in Ukrainian].
- Lund VJ, Clarke PM, Swift AC, McGarry GW, Kerawala C, Carnell D.
Nose and paranasal sinus tumours: United Kingdom National
Multidisciplinary Guidelines. J Laryngol Otol. 2016;130(S2):S111-S118.
doi:10.1017/S0022215116000530.
- Mody, M.D., Saba, N.F. Multimodal Therapy lor Sinonasal
Malignancies: Updates and Review of CurrentTreatment. Curr. Treat.
Options in Oncol.
2020;21 (1): 4. doi.org/10.1007/s11864-019-0696-4.
- Petrie A, Sabin C. Medical Statistics at a Glance. 3th ed. Oxford:
Wiley Blackwell; 2013. 180 p.
- Robin TP, Jones BL, Gordon OM, Phan A, Abbott D, McDermott JD, et
al. A comprehensive comparative analysis of treatment modalities lor
sinonasal
malignancies. Cancer. 2017 Aug 15;123(16):3040-9. doi:
10.1002/cncr.30686.
- Santos MR, Servato JP, Cardoso SV, de Faria PR, Eisenberg AL, Dias
FL, et al. Squamous cell carcinoma at maxillary sinus: clinicopathologic
data in a single Brazilian institution with review of literature. Int J
Clin ExpP athol. 2014 Dec 1;7(12):8823-32. PMID: 25674251; PMCID:
PMC4313952.
- Skomorokhova TV. [Optimization of planning and radiotherapy for
patients with upper respiratory tract tumors] [dissertation]. Kyiv:
National Cancer
Institute; 2018. 207. [in Ukrainian].
- Unsal AA, Dubal PM, Patel TD, et al. Squamous cell carcinoma of the
nasal cavity: A population-based analysis. Laryngoscope. 2016;
126(3):560-5. doi:10.1002/lary.25531.
- Vazquez A, Khan MN, Blake DM, Patel TD, Baredes S, Eloy JA.
Sinonasalsquamous-cellcarcinoma and the prognostic implications of its
histologic variants: a population-based study. Int Forum Allergy Rhinol.
2015;5(1):85-91. doi:10.1002/alr.21418.
- Zabolotny DI, Lukach EV, Dihtyaruk VJ, Tsymbalyuk EM, Zaitseva NV,
Strezhak VV, Kutsenko LB. [Five-year survival rate of patients with
malignant neoplasms of nose cavity and paranasal sinuses in Ukraine].
Rynologija. 2011;4:46-60. [in Ukrainian].
|
|